Innoviva Specialty Therapeutics announces FDA approval of Nuzolvence

Innoviva (INVA) Specialty Therapeutics, a subsidiary of Innoviva, announced that the U.S. FDA has approved Nuzolvence for oral suspension, a first-in-class, single-dose oral medication for the treatment of uncomplicated urogenital gonorrhea in adults and pediatric patients 12 years and older weighing at least 35 kg. The development of Nuzolvence was part of a private, not-for-profit collaboration with The Global Antibiotic Research and Development Partnership, which sponsored and led the Phase 3 clinical trial that supported FDA approval.